ArticleTanaffos2024
Expression of miR-155 and CEA and VEGF Proteins as Diagnostic Markers in Early Stages of Non-Small Cell Lung Cancer in Peripheral Blood.
Article in Tanaffos, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood-Based miRNA Panels for Timely Detection of Non-Small-Cell Lung Cancer: From Biomarker Discovery to Clinical Translation.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer is a disease caused by manifestation and abnormal gene expression. Many of the genes that inhibit cancer by the microRNAs. The aim of this study was to investigate the Expression of miR155 gene and CEA and VEGF proteins as Diagnostic Markers in Early Stages of Non-Small Cell Lung Cancer (NSCLC). Materials and Methods: Fifty pairs of non-small lung cancer specimens of patients from healthy and tumors were collected based on physical examination and diagnosis of an expert, that, in Masih Daneshvari Hospital. 50 healthy volunteers as a control group were volunteered by the physician after examination and filled out the consent form in this study. From all subjects, 6 ml of peripheral blood were taken and examined by Real-Time PCR (RT-PCR) and ELISA. Results: The expression level of miR-155 in patients was significantly increased compared to the control group (p<0.001). VEGF protein was positive in 34 of the 50 patients and in healthy subjects, 3 persons were positive. The statistical comparison of the amount of positive biomarker was performed in two groups and it was shown that there is a statistically significant difference between these two groups (P<0.001). CEA protein was positive in 38 of the 50 patients and 5 in healthy subjects were positive. The statistical comparison of the amount of positive biomarker was performed in two groups and it was shown that there is a statistically significant difference between these two groups (P<0.001). Conclusion: This study showed that miR155 gene and CEA and VEGF proteins are relatively good markers for the diagnosis of non-small cell lung cancer patients in Iranian population.
Indexed as
Identifiers
39703445PMC11655005What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.